ヽm

International Society for Apheresis
2 nd International Congress

Final Program - Abstracts
Saarbriicken - Germany, April 15 - 18, 1999

Table of Content

Presidential Addresses ....................................

2-4

International Society for Apheresis (ISFA).....................

5, 6

Sponsoring.............................................

7

Congress Overview ......................................

8, 9

Thursday, 15. April 1999 ..................................

10

Friday, 16. April 1999 ....................................

11 - 17

Saturday, 17 April 1999 ...................................

18 - 25

Sunday, 18 April 1999 ....................................

26 - 29

p ostersession I ..........................................

30 - 32

p ostersession II .........................................

33 - 35

General Information......................................

36 - 38

Abstracts ..............................................

39 - 194

Author Index ........................................... 195 - 199
SponsoringUnder the Patronage of His Excellency
The Prime Minister of Saarland

Mr. Reinhard Klimmt

Supported byWorld Apheresis Association (WAA)
International Society for Artificial Organs (ISAO)International Faculty for Artificial Organs (INFA)
European Society for Artificial Organs (ESAO)

Dear Participants ot the 2nc1 ISFA-Congress,
On behalf of the World Apheresis Association and it's Member Societies I am
honored and privileged to extend a cordial welcome to all the participants of the
2nd ISFA Congress in Saarbriicken, Germany.
The very optimistic prediction about the expansion of apheresis technology in theearly 80ties are now much closer to reality.WAA is the worldwide umbrella orga­
nization of today 11 international and national societies and will do everything
possible to guide and support this development by fostering international coopera­tion between professional societies, academic institutions, research centers, hospi­
tals and the relevant industry.
ISFA is one of the Member Societies ofWAA that has directed itself towards thetherapeutic application of plasma treatment by apheresis technology often in com­bination with the exciting new field of immunoadsorption.
The program of the 2nd ISFA meeting reflects the increasing interest worldwide inthis promising therapeutic approach in different fields of medicine.
Thanks to the large number und quality of the submitted abstracts, the Internatio­
nal Program Committee was able to put a sientific program together that certainlyis on of the most comprehensive presentation of its kind in recent times.
On behalf of WAA I wish you a fruitful scientific meeting and a pleasant time in
Saarbriicken.

疼私公HorstK.linkmann
President,WAA

2

Presidential Message
It is my great pleasure to welcome you to the Second Congress of the Intematio­
nal Society for Apheresis(ISFA) organized by Dr. RolfBambauer in Saarbriicken,
Saar, Germany. The First Congress was belt in Kyoto, Japan, 3 years ago, when theorganization of the Society was established. The value of apheresis therapy has
been recognized in many fields of medicine and new devices have been developed
to cure patients suffering from intractable diseases. As the life expectancy becomes
longer and longer, it is necessary to keep people in healthy state as long as possi­
ble and medical science should serve this purpose.
The apheresis therapy originally started in the form of plasma exchange. Now,
cytapheresis is attracting the attention of many physicians and researchers working
in the field of autoimmune diseases, cancer, and metabolic diseases. Apheresis the­rapy now occupies the most important part of the artificial organ. For this treatment
to continue developing, it is imperative that we expand our knowledge of medici­ne, biology, biophysics, and engeneering in order to refme our tools and techni—ques. We are confident that the scientific congress of our Society will establish astandard of excellence for this field, while providing younger physicians and tech­nical specialists with the support they need when confronted with technical pro­blems and choice of treatments.
The International Society for Apheresis is now one of the strongest constituent
society of the World Apheresis Association(W'.AA) and is expected to serve thedevelopment of the apheresis techniques in the countries and regions, where thenational societies have not yet been completely organized or are not yet so muchinternationalized. The first event(congress) is usually relatively easy; it is just likeflare. But the second one is more difficult. On behalf of the Board of Directors of
the Society, I would like to extend our gratitude to Dr. Bambauer and his Germancolleagues for organizing the second major scientific meeting overcoming manydifficulties.
Akira Yamamoto

President, International Society for Apheresis

3

Welcome in Saarbriicken/Saar, Germany
It is my great pleasure to welcome you to the SecondCongress of the International Society
for Apheresis {ISFA) to be held in Saarbriicken/Saar, Germany on April 15 - 18 (Thursday
to Sunday) 1999 under the auspices of the World Apheresis Association (W'AA), the Inter­national Society for Artificial Organs {ISAO), the European Society for Artificial Organs(ESAO), an d the International Faculty for Artificial Organs (INFA).
The ISFA was founded in Kyoto in April 1996. The first Congress successfully assembled
approximately 500 participants under the precidency of Dr. Akira Yamamoto. The official
ISFA journal "Therapeutic Apheresis" was established in January 1997. This journal will
also serve as the official publication organ for papers presented at the ISFA Congresses.
The successful application of different apheresis mo dalities are more and more recognizedin many different fields of medicine especially for the treatment of severe and refractorydiseases. New technological developments as well as medical insights have also contribu­
ted to progressive expansion of therapeutic and donor apheresis. The present congress aims
at providing the state of the art knowledge by international recognized experts as well as
encouraging scientific discussion on open problems and new approaches. With this we pro­vide a forum for interdisciplinary discussion with physicians, basic scientists and technicalaspects.
When I was given the challenge 3 years ago to organize the 2nd ISFACongress in 1999,1
agreed upon several objectives:► Wewanted to give the 2nd ISFACongress a unique identity: Showing the future, thenext millenium and what will be possible.
► Through a sequence of 2o workshops, free communications and poster sessions withthe main topics (Therapeutic plasma exchange, clinical results, selective plasmaphere­
sis techniques and clinical results, LDL-apheresis, donor apheresis, apheresis techno­
logies), we want to present the status of different apheresis technologies. Further wewant to discuss how can we sustain innovation, inform and protect the public by inclu­
ding economic, ethical and public health considerations in our activities.
► Because it is an international congress, we wanted to make a special forum for advan­
ces in the science and technology of apheresis.
► Apheresis technologies bring together physicians, clinicians, surgeons, engineers, bio­
logists and other scientists with a common interest in specialized aspects of apheresis
methods. More than 150 slide presentations, posters and different invited lectures will
focus o innovation for all disciplines.
► The 2not ISFACongress would not exist without industry contributions to research anddevelopment. The need for continous interchange of i deas between industry, scientists
and physicians is reflected in the choice of invited speakers and the invitation to start­
up companies to participate the industry exhibition which is organized during the con­gress.
► Last but not least, we have organized a social program of visits and excursions bothduring and after the congress. In April is springtfme in Germany and you can enjoy thisbeautiful season in the southwestern part of Germany. Saarbriicken, the capital of Saar­land, is situated at the border between France and Germany and looks back on a histo­
ry of more than looo years. Saarbriicken is an elegant historical city with a french
influence not far from Paris, Strassbourg, Metz, Nancy, Luxembourg and Brussels. We
want to organize on the second evening a dinner in the cultural monument Volklinger
Hiitte used to embody the Saarland 's prosperity and economic clout. Wewill do eve­rything to help ISFA participants enjoy the southwestern part of Germany.

Iィんし必

Rolf Bambauer, President of the 2 nd ISFA Congress 1999

4

INTERNATIONAL SOCIETY FOR APHERESIS
President:

Akira Yamamoto(Japan)Vice President:

Tetsuzo Agishi
Horst Klinkmann
Paul Malchesky(Japan)(Germany)(USA)

Secretary Treasure:

Masashi Kodama(Japan)Tadao Akizawa(Japan)

Editor-in Chief:

ACTING BOARD OF TRUSTEES
America

EuropeIvanovich P. (USA)
Kaplan A.
(USA)
Lentz M. R. (USA)Robinson J. A. (USA)
Sianli G.
(USA)

Borberg H.
(Gennany)
Euler H. H.
(Gennany)
Samtleben W. (Gennany)

Panpacific(Japan)Koga N.
Sekiguchi S. (Japan)
Shibuya N.
(Japan)Srivastava R. (India)
Suzuki M.
(Japan)Tsau Shin Yen(ROC)

HEADQUARTERS OFFICE:
DepartJ.nent of Surgery
Shiga University of Medical Science
Seta Otsu-shi, Shiga 520-21 Japan
Regional Office(Japan):
Regional Office(Far East):
Regional Office(Europe):
Regional Office(USA):

Hiroshi Tsuda(Japan)
Kuo-Juei Lin(ROC)
James M. CourtI1ey(UK）Yuk:ihiko Nose(USA)5

International Society for Apheresis (ISFA)
President:
Congress-President:
Scientific Secretary:
Secretary-General:
Program Chairman:
Editor-in Chief:

Akira Yamamoto
Rolf Bambauer
Jens Klinkmann
Masashi Kodama
Horst Klinkmann
Tadao Akizawa

Local Organizing Committee
T. Bosch
H. H. Euler
J. Klinlanann
W. Ramlow

W. Samtleben
J.M. Schneidewind
H. Ullrich
J. Vienken

R. E. Winkler
W. Wolf

International Advisory Board
T. Agishi(Japan)
K. Affeld(Germany)
G. Avanzi(Italy)
V. Bonomini(Italy)
B. Canaud(Franee)
M. Figuerola(Argentina)
L. Guillevin(Franee)
K. Ito(Japan)
H.Kambic(USA)A.Kaplan(USA)N.Koga(Japan)
M. R. Lentz(USA)K. J. Lin(R．0.C.)
S. Pokrowsky(Russia)
G. Rock(Canada)
D. Seidel(Germany)
G. Schmitz(Gennany)
F. Schoonemann(Franee)

N. Shibuya(Japan)
Y. Shiokawa(Japan)
G. Siami(USA)C. T. S. Sibinga(Netherlands)
R. Srivastava(India)
M. Suzuki(Japan)
L. N. Szterling(Brazil)
T. Yamaguchi(Japan)
T. S. Yen(R．O. C.)

International Program Committee
Chairman: H. Klinkmann(Germany)
T. Akizawa(Japan)
U. Baunneister(Germany)
H. Borberg(Germany)
A. Bussel(Franee)
J. Courtney(U.K.)
D. Falkenhagen(Austria)
B.R Gordon(USA)6

P. Ivanovich(USA)B. 0.Khatri(USA)E. F. Leonard(USA)P. S.Malchesky(USA)Y. Nose(USA)U. Nydegger(Switzerland)
A. A. Pineda(USA)P. Schwandt(Germany)
S. Stefoni(Italy)
B. Stegmayr(Sweden)
A. Sueoka(USA)T. Tani(Japan)
H. Tsuda(Japan)
A. Yamamoto(Japan)

key Sponsors
Biotest, Dreieich, Germany
Boehringer, Mannheim, Germany
Cilag-Jansen, Sulzbach, Germany
Fresenius, St. Wendel, Germany
Gambro, Miinchen, Germany
Kaneka, Wiesbaden, Germany
TheraSorb, Unterschleissheim, Germany
Main Sponsors
Braun, Melsungen, Germany
Diamed-Asahi, K曲In, Germany
Excorim, Lund, Sweden
Hoffmann La Roche, Grenzach-Whylen, Germany
Hospal, Miinchen, Germany
Medicap, Ulrichstein, Germany
MSD, Haar, Germany
PlasmaSelect, Teterow, Germany
Sponsors
Baxter, Immuno, Heidelberg, Germany
Centeon-Pharma, Marburg, Germany
Deutsche Apotheker- und Arztebank, Saarbriicken, Germany
Gry Pharma, Konstanz, Germany
Leo GmbH, Dreieich, Germany
Lilly, Bad Homburg, Germany
Karlsberg-Brauerei, Homburg, Germany
Medcomp, Harleysville, PA, USA
Medizintechnik, Heppenheim, Germany
Pharmacia & Upjohn, Erlangen, Germany
Rhone-Poulenc, Koln, Germany
Ulmcke-Meclizintechnik, Homburg, Germany
7

00

'、
'

゜

’

゜

Slide Presentation B

9,

闘

“

円

霞

函＇
さ，

n2

sa
w

．

Fo r
闘＿
e

目0`《
廿

嬰

s

a
- r

園

詞0 0
目0 0
且〇

’’

Be
er
-

霞

�---------

99 9 9----- ゜,-----·

OSt
裔Gro
_
1

L- - - -- --- -

|

＇
＇
-―’
·--'
'
''
''
, 0

ーサ／

f---------f-----------------＇
_
-

t>III

●

,

＼
゜
゜
閉
。
u
゜

'a

—ー

'

'
: Foyer: Kleiner Saal-- - - ----------- -‘,Saal West

SLide Presentation A

B

I

I

△

IKassenhalle|
Hauptemgang’ ’△Parkhaus
CongresshalleDdl"u International Congressof the International Society for Apheresis(ISFA)
April 15ー18, 1999
Saarbriicken, Germany
Thursday, 15.04.99
Friday, 16.04.99

IS.00-18.00 Registration
17.30 Opening Ceremony, Welcome Party, Staatskanzlei, Saarbrllcken
19.00 Concert: Ludwigskirche, SaarbrOcken
8.00 - 17.00 Registration

8.00-10.00

Apheresis in Different Parts ofthe World

I 0.00-10.30

Coffee break and visit to the ind,旧rial exhibition

10.30-12.30

Immunoadsorption in Autoimmune
Rheopheresis-Pathogenetic Mechanisms
Diseasesand Clinical Outcomes
Postersession I
with boxed Lunch
Apheresis in Systemic Lupus
Patbomecbanism-Immunomodulation
Erythematosus

12.30-14.00
14.00-16.00

II

16.00-16.30
16.30-18.00

Coffee break and visit to the industrial exhibition
Immunoadsorption in Systemic Lupus
Erythematosus

I

Cryofdtration and Plasma Fractionation

19.30 Departure Congress Center with buses to Vi!lklingen
20.00 Dinner in the Gasgeblilsehalle Vi!lklingen
Saturday, 17.04.99

8.00-17.00 Registration

8.00-10.00

Apheresis Technology

10.00-10.30
10.30-12.30

16.00-16.30
16.30-18.00

Apheresis in Haematology and
Neurology

8.00-10.00
10.00-10.30

Apheresls In Neurological Disorders

12.30-13.QO

Apheresis in Surgery andTransplantation

Coffee break and visit to the industrial exhibition
Current Status and Futureof Adsorption Technologies|

Apheresis In Sepsis

General Assembly
20.00 Gala-Dinner in the Congress Center, Saarbrllcken
08.00 Registration
LDL-Apheresis I

Preparative Hemapheresls

LDL-Apberesis U

Leukocyte Filters and their
Immunomodulation
Vascular Access
Closing Ceremony

Photooheresis|
Coffee break and visit to the industrial exhibitionI，

10.30-12.30

I

Apheresis in Critical Care

Postersesslon II
with boxed Lunch

18.00-18.30

Sunday, 18.04.!l!I

Apheresis - Varia

Coffee break and visit to the industrial exhibition

12.30-14.00
14.00-16.00

II15.00-18.00
17.30
19.00
15.00-17.00

Registration
Opening Ceremony, Welcome Party, Staatskanzlei,
Saarbriicken
Concert: Ludwigskirche, Saarbriicken
Satellite Symposium: Challenge in the Management of
Diabetes mellitus: Established and new therapeutic
approaches
Chair: Solimena M(USA) & Schiel R (Germany)
Pathogenesis of diabetes mellitus. New autoantigens oftype 1 diabetes mellitus
�Yale University, New Haven, USA
Current quality of diabetes care in Germany
the results of population-based surveys
� Friedrich-Schiller-University, Jena, Germany
How to improve care for type 2 diabetic patients?
V.J6rgens andM.G戊sgr, Heinrich-Heine-University,
Dusseldorf and Zentralinstitut der Kasseniirztlichen
Vereinigung fur die Versorgung der Bundesrepublik
Deutschland, Cologne, Germany
The challenge to treat type 1 diabetes.
fL..A..MjjJJgr, Friedrich-Schiller-University, Jena, Germany

10Apberesis in Different Parts of the World
Chair: Klinkmann H (Germany) & Bambauer R (Germany)
Future Aspects and New Developments in Plasmapberesis
必(USA) - Introductory Lecture Apheresis Registry in France - Indication, Techniques and Complications
�(France)
Practical Use of Therapeutic Apheresis in Japan� Takenaka M, Sanaka T, Tuda Y (Japan)
Evidences for Multifactorial Effects of LDL
Adsorption on Vascular diseases
�(Japan)Current Status of Therapeutic Apheresis in Taiwan
Lirl..Kl.(Taiwan)
Clinical Results of Three Hundred and Fourteen Treatments with
Double Filtration Plasmapberesis
LiM..lJ.2., Li WS, Lun W, Zhu X, Gu Q (PR China)
Apheresis Activities in India
� (India)
An Overview on Therapeutic Plasmapheresis
� (Brasil)
Patient Registry for LDL Apheresis: Design and Initial Results� (USA)11

lmmunoadsorption in Autoimmune Diseases
Chair: Schneider M. (Germany) & Derfler K. (Austria)
Immunoadsorption for the Treatment of Rheumatoid Arthritis
�(USA)
Primary Vasculitis
�(UK)Immunoadsorption in Guillain-Barre Syndrome and Myasthenia Gravis
� Rosenow F, van der Ven C, Birkmann C (Germany)
Immunoadsorption in Dilated Cardiomyopathy!liirJk1..J¥Y, Staudt A, Baumann G, Felix S (Germany)
A New Immunomodulatory Treatment Regime in Aquired Hemophilia withIgG Therasorb Immunoadsorption -A Modified Bonn Protocol'Zei1kI.1l, Nettekoven W, Stier S, Hess L, Effenberger C, Brackmann B, Vetter H(Germany)
Inhibitor Associated Haemophilia - Experience of Immune Adsorption using
Protein A� Bemtorp E, Nilsson IM (Sweden)
Long-Term IgG-Immunoapheresis in Highly Sensitized Renal Transplant
Recipients� Sautner TH, Hori WH, Banyai S, Streicher J, Jansen M, Mayer W,
Druml W (Austria)

12.30-14.00

12

Postersession I
Chair: Szterling L (Brazil) & Srivastava R (India)

Rheopheresis - Pathogenetic Mechanisms and Clinical Outcomes
Chair: Gfunbel H (Germany) & Kiesewetter P (Germany)
Rheopheresis- Rheologic, Functional and Structural Aspects
� Fassbender B, Erdtracht B (Germany)
Specific Microrheological Effects of a.2-Macroglobulin in vitro and in vivo:
causes and consequences of 'Clump Aggregation'
� Gallasch G, Goebel H, Horstkott H, Heidtmann H (Ger­many)
The Impact of Endothelial Function on Diseases with Impaired
Microcirculation
� (Belgium)
Improvement of Visual Acuity after Elimination of High-Molecular-Weight
Proteins and Lipids by Membrane Differential Filtration in Patients with
Age-Related Macular Degeneration
� Brunner R, Walter P, Soudavar F, Luke C, Fisher R, Heimann K,
Borberg H (Germany)
Improvement of Visual Acuity and Visual Field in Patients with Diabetic
Retinopathy after Membrane Differential Filtration
� Widder RA, Soudavar F, Walter P, Brunner R, Heimann K, Borberg H(Germany)
Rheopheresis -A Promising New Treatment for Age-Related Macular Dege­
neration
Swartr『 M, Rabetoy G, CheungA, Davis R (USA)
Potential of Rheopheresis for the Treatment of Acute Ischemic Stroke
R6sslerA, Be汀ouschot J, Barthel H, Koster J, Schneider D (Germany)

13

Apheresis in Systemic Lupus Erythematosus
Chair: Euler H (Germany) & Guillevin L (France)
Synchronization of Plasmapheresis and Adjuvant Treatment in Autoimmune
Diseases
EYJ&L.1Jll. (Germany)
Synchronization of Plasma Exchanges and Adjuvant Treatments
� (France)
Plasmapheresis Helps to Reduce Cytotoxic Drugs in the Management of
Severe Systemic Lupus Erythematosus (SLE)
Klln..EM_, Rech J, Manger B, Kalden JR (Germany)
Successful Treatment of Systemic Lupus Erythematosus By Clq-Immuno­
adsorption
Pfueller B, Wolbart K, Bruns A, Leinenbach HP, Hepper M, Otto V, Burmester
GR, Hkof:_E (Germany)
Therapeutic Plasma Exchange and Cyclosporin in the Treatment of Systemic
Lupus Erythematosus
Bambauer R, � (Germany)
Immunomodulatory Treatment of Autoimmune Disease Synergy
between Plasma Exchange und iv Immunoglobulins
� (Schwitzerland)
Plasma Exchange in Treatment of Rapidly Progressive Glomerulonephritis
Especially ANCA - positive Nephritis
Sw.ir.t..JYM.(Denmark)14

Friday, 16 April 1999 14.00-16.00
Pathomechanism - Immunomodulation
Chair: Pineda AA (USA) & Ramlow W (Germany)
Immunomodulation by Apheresis
� (USA) - Introductory Lecture Removal of Autoantibodies by Extracorporeal Immunoadsorption (IA)-Does
it Truly Matter?
� Michelsen A, Hofmann D, Winkler RE, Tiess M, Schneidewind JM,
Weber G, K,窃sser M, Millier W, Kinze E, Ramlow W (Germany)
Changes in Lymphocytic Subpopulations During Apheresis Treatment
� Ramlow W, Winkler RE, Tiess, M, Reinke P, Docke W, Volk
HD, Michelsen A, Hofmann D, Weber G, Prophet H, Kinze EM, Millier W, Klink­mann H (Germany)
Immunoglobulin Production in Peripheral Blood Mononuclear Cells after
Antibody-Based Immunoadsorption Therapy
� Tuma E, Sitter T, Muller-Felber W, Pongrat D, Schiff[ H (Germany)
Can Fibronectin-IgG-Complexes Pretend Anti-ClQ Autoantibodies inPatients with SLE?
� Bruns A, Kuhn S, Hiepe S (Germany)
Adhesion Molecules Expression in Familial Hypercholesterolemia Patients
who Underwent Long-Term DFPP Treatment
� Motohashi K, Suzuki H, Matsugane T, Nobuto T, Azuma N, Nishide T,
Suzuki M (Japan)

15

Friday, 16 April 1999 16.30-18.00
Immunoadsorption in Systemic Lupus Erythematosus
Chair: Schneider M. (Germany) & Braun N. (Germany)
Introduction
�(Germany)
Clinical Experiences using Protein A
l'm!J2g____JJ. (UK)Identification of Disease Relevant Antigens in Eluates from SLE Patients
undergoing Immunoadsorption onto Staphylococcal Protein A&mm.l:L_ Jakubetz HJ, Gutenberger S, Risler T (Germany)
Treatment with Dextrane Sulfate-Cellulose Columns
�(Japan)High Volume Immunoadsorption using Ig-T herasorb as Treatment in Severe
Systemic Lupus Erythematosus
� Fischer R, Specker C, Schneider M (Germany)
Immunoadsorption in Systemic Lupus Erythematosus: Randomised Trial of
two Adsorbers
� Seidel M, Schotte H, Schneider M, Domschke W (Germany)16

Cryoftltration and Plasma Fractionation
Chair: Malchesky PS(USA) & Sueoka A (Japan)
Introduction
Malches灼f_ (USA)
Possibilities and Limitations of Membrane Fractionation
�(Japan)Membrane Plasma Fractionation in the United States� Siami FS (USA)
Separation / Selective Sorption(S/SS) Technology for Safe, Rapid and Sim­
ple Removal of Molecules from the Blood: The Device Based Approach� Malchesky PS (USA)Push-Pull Sorbent-Based Pheresis(Biologic-DTPF System') in Treatment of
Systemic Inflammatory Response Syndrome(SIRS)
� Levy H, Steczko J, Carr DJ, Blake DE (USA)17Apheresis Technology
Chair: Vienken J (Germany) & Koll R (Germany)
Membrane Technologies in Apheresis Methods
Vienken J (Germany) - Introductory Lecture_
Membrane Plasma Fractionation: 12 Years Experience
Sim11i...E£ Siami GA (USA)Elimination of Immunoglobulin Classes by a Protein A Versus an Anti—
Human-Immunoglobulin-Antibody Based System: Evaluation of 602
Sessions of Extracorporeal Immunoadsorption (IA)Mfl1k...QJl, Michelsen A, Hofmann D, Winkler RE, Tiess M, Schneidewind JM,
Weber G, Keysser M, Muller W, Kinze E, Ramlow W (Germany)
A New Module Arrangement for Plasma Apheresis
� Hilke R, Weidemann S, Groth Th, Weigel Th, Paul D, Plagge A (Ger­many)
Therapeutic Apheresis in Children Technical Difficulties and Clinical
Indications
D!:....fgjQI, Bellantuono R, Collella V, Giordano M, Caringella AD (Italy)
Comparison of Fresh Frozen Plasma (FFP) with a Standardized Serum Pro­
tein Solution(Biseko®) Following Membrane Plasma Separation in Patientswith Autoimmune Disease (A Prospective Controlled Clinical Trial)
Keller E, Beeser E, Peter HH, Arnold A, � (Germany)
Use of Plasmapheresis in Dialysis Centre - 15 Years Experiences
Myfi1ik..M., Derzsiovti K, Mizia P (Slovak Republic)18

Apheresis - Varia
Chair: Kawamura A (Japan) & Klinkmann J (Germany)
Apheresis: DitTerent Techniques - Similar Results� ( Germany)
Immunoadsorption and Plasma Exchange in Dermatology
Wl!:iJ;h_Jl, Stolz W, Hohenleutner S, Lackner. K, Landthaler M, Schmitz G(Germany)
Immunoadsorption Improves Cardiac Performance in Patients with Severe
Dilated Cardiomyopathy� Wallukat G, Dandel M, Bieda H, Hummel M, Hetzer R (Germany)
Application Extracorporeal Blood's Purification for Treatment Arrhythmias
of Heart
Nedostup AV.� Soloviova LN, Panasiuk VV. Tzaregorodtsev DA, Bol­
direv DA, Ivanov MI, Alekseeva IA (Russia)
A Comparative Study Between Plasma Exchange andlmmunoadsorption on the Removal of ANCA
� Segelmark M, Freiburghaus C (Sweden)
New Lymphocytapheresis(LCAP) Technique for Cytokine Control-Application to Int1am:matory Bowel Disease(1BD)� Saitoh M, Yonekawa M, Hanamoto T, Osanai M, Hanada H,
Masuko Y, Yasuhara M, Tanaka M, Tamaki T, Kukita K, Meguro J, Ohizumi H,
Konoeda Y (Japan)
82-Microglobulin Adsorption in Chronic Hemodialysis Patients Associatedwith Dialysis-Related Amyloidosis(gjyQE...(Japan)
Erythrotapheresis - Clinical Results
Kiesewetter P (Germany)

19Apheresis in Haematology and Neurology
Chair: Kaplan A(USA) & Ivanovich P(USA)
Therapeutic Plasma Exchange in the Treatment of Cancer RelatedHemolytic Uremic Syndrome(HUS)
K!mkm..M (USA) - Introductory Lecture Prospective Randomised Multicenter Study in Thrombotic
Microangiopathy(Prodromi)� Krumme B, Rump LC for the PRODROMI Study Group (Germany)
The Efficacy of Continuous Plasma Exchange and Sequential
Continuous Hemodiafiltration(CPE + CHDF) for Thrombotic
Thrombocytopenic Purpura/Hemolytic Uremic Syndrome(TTP/HUS)
� Hirasawa H, Sugai T, Oda S, Shiga H, Nakanishi K, Kitamura N,
Sadahiro T, Yokohari K (Japan)
Antibody-based Immunoadsorption in Peripheral Neuropathy
Associated with Benign Monoclonal lgM Paraproteinaemia
� Schroeder M, Reilich P, Sitter T, Hirschmann M, Pongratz D,
Schiffl H, Muller-Felber W (Germany)
Optimal Volume of Plasma Treated and Numbers of Plasmapheresis
in the Treatment of Myasthenia Gravis
Y4.lll, Chiu HC (Taiwan)
Comparison Between Immunoadsorption and Double Filtration
Plasmapheresis in the Treatment of Myasthenia Gravis
� Yeh JH (Taiwan)
Treatment by Plasma Exchange in two Patients of Hereditary
Polyneuropathy with Recent Aggravation
Qw:J,_JfJi, Yang CC, Hsieh ST (Taiwan)
L-Tryptophan degrading Bioreactor
�(USA)
12.30 - 14.00
20

Postersession II
Chair: Matic C (Germany) & Valbonesi (Italy)Apheresis in Critical Care
Chair: Falkenhagen D (Austria) & Hirasawa H (Japan)
NewAdsorption Technologies -A Necessity for Intensive Care Medicine
� Strobl W, Vogt G, Scherjl A, Lindsberger I, Loth F, Kramer L,
Losert U, Schima H, Loth F, Schoenhofen M (Austria)
Development andApplication of anAdsorption-Apheresis Procedure for the
Elimination of Endotoxins and Lipoteichoic Acids from Human Plasma� Boos K-S, Samtleben W, Inthom D, Seidel D (Germany)
Push-Pull Sorbent-Based Pheresis(Biologic-DTPF™)in treatment of
hepatic failure: Preliminary Results of a Clinical Trial
� Blake DE, Carr DJ, Harker KD, Levy H (USA)
Effect of Endoto:xinAdsorption with Polymy:xin B Immobilized
Fiber on Hemodynamics in Severe Sepsis
� Ogata H, Akizawa T, Takahashi Y (Japan)
Therapeutic Plasma Exchange(TPE)for Fulminant Hepatic Failure(FHF)inlCU
� Sugai T, Oda S, Shiga H (Japan)
Plasmaexchange(PE)May Improve Survival of Patients with
Multiorgan Dysfunction Syndrome(MODS)IncludingAcute Renal Failure� Norda R, Banga R, Rydvall A (Sweden)
Cytokine changed in Patients with Multiple Organ Failure Treated by
Plasmapheresis
LiD....KJ., Yang MD (Taiwan/Japan)
Therapeutic Plasma Exchange in the Treatment of Nontraumatic
Rhabdomyolysis withAcute Renal Failure� Klobe R, Gernert S (Germany)

21

Apheresis in Neurological Disorders
Chair: Khatri BO(USA) & Haupt WF (Germany)
Science and Ethics of Apheresis in Neurological Disorders
�(USA)
Apheresis in Acute Multiple Sclerosis - A Double Blind
Randomized Cross-Over Trial
�(USA)
Apheresis in Chronic Multiple Sclerosis
KhfJ1li1JQ (USA)
Apheresis and Combination Therapy in Guillain-Barre Syndrome�(Germany)
Apheresis in Chronic Inflammatory Demyelinating Polyneuropathy
�(Japan)Therapeutic Apheresis in Neurological Diseases in Japan�(Japan)22Apheresis in Surgery and Transplantation
Chair: Agishi T (Japan) & Kodama M (Japan)
Membrane Auto-transfusion System (Mats)� Shimoyama T, Sawada K, Drake M, Mueller J, Sueoka A, Nose Y(Japan/USA)
Correlation between Plasma Endotoxin, Plasma Cytokines andPlasminogen Activator Inhibitor-I Activities in Septic Patients
Tanじ[, Hanasawa K, Kodama M, Imaizumi H, Yonekawa M, Saito M, Ikeda T,
Yagi Y, Takayama K, Amano I, Shimaoka H, Ohta M, Katayama H, Okahisa T,
Kato M, Koga M, Fujita N (Japan)
Efficacy of Continuous Hemodiafiltration in the Management of
Postoperative Multiple Organ Failure� Sugai T, Oda S, Shiga H, Matsuda K, Kitamura N, Kawakami M(Japan)Plasmapheresis plus Continous Hemodiafiltration as a Bridge to
Living Related Liver Transplantation for fulminant Hepatic Failure� Fuchinioue S, Nakajima I, Tojimbara T, Agishi T,
Takasaki K, Tanaka K (Japan)
Removal of Anti-A/B Antibodies using DFPP in ABO Incompatible
Kidney Transplantation
� Tanabe K, Ishikawa N, Tokumoto T, Oshima T,
Fuchinoue S, Takahashi K, Toma H, Agishi T (Japan)
Extracorporeal Immunomodulation by Cryofiltration in Transplantation
Qgmgj__M., Kawamura A, Yonekawa M (Japan)

23

Current Status and Future of Adsorption Technologies
Chair: Bosch T (Germany)
Adsorption Technology - Quo Vadis?
� Leinenbach HP, Kannenberg A, Zimmermann M (Germany)
In Vitro Endotoxin Adsorption Properties and In Vivo
Hemocompatibility of Immobilized Human Serum Albumin� Hepper M (Germany)
LDL-Apheresis using the DALI-System - State of the Art
� (Germany)
Safety and Adsorption Kinetics of the Clq-Adsorber
叫Matic W, Drobnik W, Ullrich H, Gluck T, Pickenpack A,
Barlage S, Porch-Ozc叩mez M, Klucken J, Lang B, Lackner K,
Rothe G, Schmitz G (Germany)24Apheresis and Plasma Exchange in Sepsis
Chair: Stegmayr B (Sweden) & Bosch T (Germany)
w畑tTo:xins are Expected to be Released from Bacteria Such asGroup A Streptococcil:lJ11m..£..(Sweden)
Pathophysiology of Septic Shock and MODS and Various
Therapeutical Approaches with Special Emphasis on Immunoglobulins
We油rA..K. (Genrumy)
Apheresis asTherapy for Patients with Severe Sepsis and MODS
�(Sweden)Analysis of Efficiency of Plasmapheresis in the Treatment of Severe
Sepsis and Septic Shock: A Prospective, Randomized, Clinical Trial.
� Utrobin U, Busund R, Nedashkovsky E (Russia/Norway)
Apheresis Technologies in CancerTherapy
�(USA)

25

LDLApheresis I
Chair: Yamamoto A (Japan) & Richter WO (Germany)
Can Statin Benefit Patients with Homozygous Familial
Hypercholesterolemia on LDL-Apheresis?
� (Japan) - Introductory Lecture Efficacy of DitTerent LDL-Apheresis Methods
�(Germany)
Evidences for Multifactorial Effects of LDL Adsorption on Vascular Diseases
�(Japan)Long-Term Assessment of LDL Apheresis to Heterozygous Familial
Hypercholesterolemia� Shiba-Han叫a M, Ryomoto K, Tsushima M, Yamamoto A (Japan)
LDL-Apheresis in Treatment of Hyperlipidaemia -A Comparison ofFour DitTerent Technologies
Bambauer R, � La,tza R (Germany)
A Trial of LDL-Apheresis T herapy for Uremic and Diabetic Neuropathy
� Himuro K, K.urioka K, Yamada A, Maruyama T, m叫aS (Japan)
HELP-Report 1999: An Update of Clinical and Experimental
Studies on Heparin-Mediated E:xtracorporeal LDL/Fibrinogen Precipitation
� Seidel D (Germany)
Long-Term Results of LDL-Apheresis with DitTerential Filtrationv• Ba町� Schwart[ M, Schwerdtfeger R (Germany)

26

Preparative Hemapheresis
Chair: Nydegger U (Switzerland) & Schoonemann F (France)
Multicomponent Blood Donation by Apheresis
� (Germany)
Platelet Concentrates with Trima: Preliminary Results� Claise C (France)
New Procedure for the Inline Separation of Whole Blood
� Basser S, Wohlgemuth L, Geigle P (Germany)
Development of Rapid Blood Transfusion System with a Capabilityof Blood Purification
� Notoya T, Kumagai M, Takada G (Japan)
Sunday, 18 April 1999 09.00 - 10.00 am

Photopheresis
Chair: Knobler R (Austria) & Robinson J(USA)Photopheresis in Heart and Lung Transplantation
� (USA)
Extracorporeal Photoimmunotherapy in 1999
Kn!2l2kLB. (Austria)
6 Years Experience with Photopheresis Procedures: A Critical Look� Claise C (France)
Apheresis in the Treatmant of Haematological Disorders� (Germany)
Transfusion Technologies Today

Zeyler T (Germany)27

LDL-Apheresis II
Chair: Schuff-Werner P (Germany) & Schwandt P (Germany)
Lp(a) Apheresis: Patient Selection Criteria
� Avanzi G, Cesaretti S, Lepori M, Lombardo P, Cepparrone F (Italy)
Lp(a) Reduction by LDL-Immunoapheresis
� Streicher J, Gabriel H, Hori WH, Derfler K (Austria)
Direct Adsorption of LDL and Lp(a) from whole Blood:
Interim Analysis of a Clinical Long-Term Study
l1JlEh.I, Schenzle, Drager J (Germany)
LDL-Apheresis: Longitudinal Study of Three Patients Treated withDALI and HELP� Kassner U, Miinzberg H, Steinhagen-Thiessen E (Germany)
Influence of Whole Blood and Plasma LDL-Apheresis on theantioxidative status of plasma in patients with familial hypercholesterolemia
Schram町� Jue D, Kontush A, Beisiegel U, Beil U
Influence of two Selectived LDL-Apheresis Procedures (DALI and HELP)
on Blood Coagulation,/yJjy,§_Jj_, Gromeier S, Siegert G (Germany)
LDL Apheresis by Dextransulfate Adsorption in Patients under Oral
Anticoagulation
� Basser S, Wohlgemuth L, Seeger W, Heine C (Germany)
DALI LDL-Apheresis: Therapy without Heparin is a Safe Procedure� Kassner U, Miinzberg H, Steinhagen-Thiessen E (Germany)28

Leukocyte Filters and their Effect on Immunomodulation
Chair: Nose Y(USA) & Sawada T (Japan)
Therapeutic Apheresis in Ulcerative Colitis
�(Japan)
Leukapheresis for Patients with Rheumatoid Arthritis
� Amano K (Japan)
Aggressive Combination Therapy with Leukocytapheresis(LCP) and
Double Filtration Plasmapheresis(DFPP) for the Treatment ofRheumatoid Arthritis (RA) Patient with Vasculitis
� Kim YI, Yamaji K, Miyatata S, Moriya Y, Kida I, Kanai Y, Tsuda H,
Takasaki Y, Hashimoto H (Japan)
Lymphocyte Removal by Thoracic Duct Drainage
� Agishi T, Starzl TE (Japan/USA)

Vascular Access
Chair: Bambauer R (Germany) & Canaud B(Franee)
Temporary Vascular Access for Extreorporeal Therapies
�(France)
Surface Treatment of Catheters for Prevention of Infection and Thrombosis
�(USA)
Surface-Treated Catheters with Ion Beam-Based Process for Blood Access� Schiel R, Mestres P (Germany)
Scanning Electromicroscopy Investigations in Artificial Organs
Mmm..E_ (Germany)

29

Postersession I
Chair: Szterling LN (Brazil) & Srivastava R (India)
1

2 Cases of Wegener's Granulomatosis (WG) - Experience with
Extracorporeal Immunoadsorption (IA, Excorim and/or Therasorb)
� Michelsen A, Hofmann D, Winkler RE, Tiess M,
Schneidewind JM, Weber G, Kinze E, Ramlow W (Germany)

2

Plasmapheresis for Patients with Myeloperoxidase Anti-Neutrophil
Cytoplasmic Antibody
� Torikoe Y, Miyakata S, Moriya Y, Yang K, Kida I, Matsuda Y,
Kamaji K, T suda H, Takasaki Y, Hashimoto H (Japan)

3

Therapeutic Plasmapheresis for the Treatment of Pregnant Systemic
Lupus Erythematosus Patients with Antiphospholipid Antibodies
Yfmg_K, Yamazaki Y, Kimura K, Kim YJ,Kenpe K, Miyakata S, Moriya Y,
Watanabe, H, Kida /, Matsuda Y, Yamaji K, Kanai Y, T suda H, Takasaki Y,
Hashimoto H (Japan)

4

Protein A Immunoadsorption (IA) in a Pregnant Woman with Habitual
Abortion� Korten G, Barz D, Anders 0, Ohde A, Muller H, Bolz M(Germany)5

Successful Treatment of a Patient with Lupus-Nephritis by
Cl Q-Immunoadsorption
� Pfueller B, Wolbart UK, Leinenbach HP, Hepper M, Hiepe F(Germany)

6

Coupling DNA to Epichlorohydrin-Activated Cellulose as
Immunoadsorbent for Systemic Lupus ErythematosusK£mg_J)L Yu YT (RP China)

30

Postersession I(continued)
Chair: Szterling LN(Brazil) & Srivastava R(India)
7

Experience With a Combined Treatment of Chronic Therapeutic
Plasmaexchange and Mycophenolate in a Case of Mixed Connective
Tissue Disease(MTCD) with Severe Hypertension
� KingreenH (Germany)

8

The Therapy Refractory Sharp Syndrome(MCTD, Mixed Connective
Tissue Disease) -A Case of Successful Treatment with Extracorporeal
Immunoadsorption(IA）� Matic GB, Hofmann D, Winkler RE, 1iess M, Schneidewind JM,
Weber G, Michelsen A, Kinze E, Ramlow W (Germany)

9

Treatment of Scleroderma with Double Filtration Plasmapheresis
� Ohshita H, Hino N, Uda H, Saiki O (Japan)

10 Kinetics of Thyroid Hormones During Plasma Exchange with Fresh
Frozen Plasma in a Patient with Severe Hyperthyroidism
� Krause B, Hornberger J, Saul Fw, Li.ぅ'sse B (Germany)
11 Treatment of a Refractory Case of Endocrine Ophthalmopathy (E0)with Extracorporeal lmmunoadsorption(IA）� Matic GB, Hofmann D, Winkler RE, 1iess M, Schneidewind JM,
Weber G, Michelsen A, Kinze E, Hampel R, Ramlow W (Germany)
12 Limb Salvage in Acute Devastating Thrombangiitis Obliterans by
Means of Help Apheresis
� Schellong S, Julius U (Germany)
13 A Novel Method for Selective Removal of Circulating Immune
Complexes
Gro針0加l1l111., Ramlow W, Boeden H, Klemke Th, Kruschke P, Kong DL,
Matic GB, Hofmann D, Kunkel S, Holtz M, Klinkmann J, 1iess M,
Winkler RE, Yamada R, Schutt W (Germany/Japan)

31

Postersession I (continued)
Chair: Szterling LN(Brazil) & Srivastava R (India)
13 Praticle Release in Extracorporeal LDL Lowering Therapies
M!mirJ:s...K, Ahrenholz P, Matic GB, Hofmann D, Thiess M, Winkler RE,
Ramlow W (Germany)
14 Controlled Clinical Study to Compare the Efticay and Tolerance of the
Two Plasma Exchange Preparations: Human Serum Protein Selection(HSP)and Human Albumin(HA）in Patients with Autoimmune
Diseases.
Bambauer R,..Am叫(Germany)
15 The Effect of Filtration Leukocytapheresis Therapy on Various
Cytokine Concentrations in the Circulating Blood and Synovial
Fluid of Patients with Rheumatoid Arthritis
lJjgg/s,g._I, Suzuki K, Kawakami M, Kataharada K,
Takamizawa-Matsumoto M, Okada M, Matsuki Y, Ohsuzu F (Japan)
16 Immunomodulatory Role of Plasmapberesis in Al的losing Spondylitis
� Vishwakarma GK (India)
17 Double Filtration Plasmapberesis in Treating紅曲rlosing Spondylitis:
Clinical Study in 20 Cases
Lm..lJ2, Li WS, Zhu X, Shang S, Zhang C, Gu Q, Wu J (PR China)
18 Improvement of Inner Ear Hearing Loss Associated with MonoclonalGmnmopathy of Undertermined Significance(MGUS)Using
ClQ-Immunoadsorption
� Pfueller B, BrunsA, Leinenbach HP, Hepper M, Hiepe F(Germany)
19 Extracorporeal Immunoadsorption for Urticaria Vasculitis andMonoclonal Gmnmopathy of lgM Type� Blasum C, PatzakA, Wildbrett J, Wozel G, Meurer M (Japan)

32

Postersession II
Chair: Matic GB (Germany) & Valbonesi (Italy)
20 Plasmapheresis in Myasthenia Gravis -Comparative Study of Daily
versus Alternately Daily Schedule
YdLlll, Chiu (IC (Taiwan)
21 Therapy df Chronic Idiopathic Demyelinating Polyradiculo-Neuropathy
with Intermittent Immunoadsorption -A Case Report� Deuber HJ, Koall W, Osten B (Germany)
22 Effect of Immuno-Adsorption Therapy for Autoimmune Neuropathy!Js&ig_J, Kohriyama T, Kozuka K, Harada A, Nakamura S (Japan)
23 Therapeutic Plasma Echange (TPE) in Treatment of
Adrenoleucodystrophy (ALD)
Bambauer R, � (Germany)
24 Effect of Plasma Exchange (PE) on a Refractory Hemophagocytotic
Syndrome (HPS) Complicated with Myelodysplastic Syndrome (MDS)� Nagai S, Nagai T, Niikura K, Akizawa T, Ideura T (Japan)
25 Rapid Reduction of Platelet Count in Thrombocytosis
� Centoni PE, Sodini ML (Italy)
26 Plasma Exchange (PE) for Aquired Hemophilia -A Case Report
QggJg__Jl, Saka.i, S, Koiwa F, Tayama H, Kinugasa E, Akizawa T (Japan)
27 Role of Plasmapheresis in Inflammatory Bowel Disease-Ulcerative Colitis
� (India)33

m』細裏 輝顧麗9，、「む覇贔曹
9i 」
i
ら

Postersession II (continued)
Chair: Matic G (Germany) & Valbonesi (Italy)
28 Off-Line Leukopheresis System for the Treatment of Ulcerative Colitis
Enf!,QX, Tani T, Tsuzuki H, Kondo H, Fujino M, Hanasawa K, Kodama M(Japan)29 Plasmapheresis Clinical Results, New Aspects
�(India)
30 Plasmapheresis after Heart Transplantation
� Alexeeva LA, Soloveva IN, Dzemeshkevich SI (Russia)
31 Long Term Immunoadsorption in Recurrent Idiopathic Nephrotic
Syndrome after Renal Transplantation
� Savin VJ, Rump LC(Germany./USA)
32 LDL-Apheresis in Glomerulonephritis, Nephrotic Syndrome, andThrombosis of V. Cava -A Casereport� Heine C(Germany)
33 Cyclic Nucleotides During Low Density-Lipoprotein Apheresis
� Yoshitomi Y, Saotome M, Matsumoto Y, Yano M, Kuramochi M(Japan)34 The Influence of Plasmapheresis on the Blood Resting Levels ofSuperoxide Anion in Uremic Patients� Chen MF (Taiwan)
35 Neutrophil Activation in Imm.unoadsorption
Ota K, Shimizu Y, Ueda M, Akiyama N, Higuchi C, Agishi T, Iwata M (Japan)

34

Postersession II (continued)
Chair: Matic G (Germany) & Valbonesi (Italy)
36 A New Method for Removal Albumin-Binding Uremic Toxins:
Efficacy of an Albumin-Dialysate
Af:zu_,fI, Ageta S, Shono M, Uematsu I, Kodama T, Kobata T, Abe T,
Suzuki N, Hirata H (Japan)
37 lmmunoapheresis Alters Peripheral Type 1 and Type 2 T-Cell Cytokine
Production Profiles in Patients with Refractory Autoimmune Diseases
� Salzsieder E, Matic G, Ramlow W (Germany)
38 Comparisons of lmmunomodulation Effect on Hepatic Xenograft by
Cyclosporin A and Azathioprine in Rabbits
� Mathur AK, Gupta N, Mathur DR, Sharma P, Srivastava R (India)
39 Platelet Membrane Markers Evaluation of Three Apheresis Concentrates
� Claise C (France)
40 Donor Apheresis: Platelet Apheresis Donation
� (France)
41 Amicus Platelet Pheresis Procedures Comparison Bipuncture andUnipuncture� Claise C (France)
42 Donor Apheresis - Role in Transfusion Transmitted Diseases in India
Lalchandani A, Srivastava R (India)
43 Donor Apheresis - Role in Transfusion Transmitted HIV in India
Lalchandani A, Srivastava R (India)
44 Efficacy of Donor Apberesis in Preparation & Preservation of Blood
Components
� Srivastava R (India)

35